Total Payments
$9,198
2021 Payments
$1,148
Companies
5
Transactions
26
Medicare Patients
738
Medicare Billing
$80,762
Payment Breakdown by Category
Consulting$4,488 (48.8%)
Research$3,339 (36.3%)
Travel$1,159 (12.6%)
Food & Beverage$211.60 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $4,488 | 3 | 48.8% |
| Unspecified | $3,339 | 12 | 36.3% |
| Travel and Lodging | $1,159 | 5 | 12.6% |
| Food and Beverage | $211.60 | 6 | 2.3% |
Payments by Type
General
$5,858
14 transactions
Research
$3,339
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $4,208 | 2 | $0 (2021) |
| Biogen, Inc. | $3,339 | 12 | $0 (2019) |
| UCB Biosciences Inc. | $1,355 | 10 | $0 (2017) |
| VERTEX PHARMACEUTICALS INCORPORATED | $280.00 | 1 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $15.60 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $1,148 | 1 | Alexion Pharmaceuticals, Inc. ($1,148) |
| 2020 | $3,076 | 2 | Alexion Pharmaceuticals, Inc. ($3,060) |
| 2019 | $2,579 | 2 | Biogen, Inc. ($2,299) |
| 2018 | $1,040 | 11 | Biogen, Inc. ($1,040) |
| 2017 | $1,355 | 10 | UCB Biosciences Inc. ($1,355) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2021 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,148.00 | General |
| 07/22/2020 | Alexion Pharmaceuticals, Inc. | Soliris (Drug) | Consulting Fee | Cash or cash equivalent | $3,060.00 | General |
| Category: Immunology | ||||||
| 05/20/2020 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: CNS | ||||||
| 09/13/2019 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $280.00 | General |
| 05/30/2019 | Biogen, Inc. | — | — | Cash or cash equivalent | $2,299.11 | Research |
| Study: An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) | ||||||
| 08/26/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $64.98 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/26/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $53.94 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/26/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $48.80 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/25/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $134.36 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/25/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $64.98 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/25/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $53.94 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/25/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $48.80 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/24/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $319.31 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/24/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $105.00 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/24/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $85.74 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/24/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $60.50 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 06/03/2017 | UCB Biosciences Inc. | — | Travel and Lodging | In-kind items and services | $125.00 | General |
| 06/03/2017 | UCB Biosciences Inc. | — | Food and Beverage | In-kind items and services | $38.00 | General |
| 06/03/2017 | UCB Biosciences Inc. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 06/03/2017 | UCB Biosciences Inc. | — | Food and Beverage | In-kind items and services | $20.00 | General |
| 06/03/2017 | UCB Biosciences Inc. | — | Food and Beverage | In-kind items and services | $20.00 | General |
| 06/02/2017 | UCB Biosciences Inc. | — | Travel and Lodging | In-kind items and services | $521.39 | General |
| 06/02/2017 | UCB Biosciences Inc. | — | Travel and Lodging | In-kind items and services | $340.86 | General |
| 06/02/2017 | UCB Biosciences Inc. | — | Travel and Lodging | In-kind items and services | $125.00 | General |
| 06/02/2017 | UCB Biosciences Inc. | — | Food and Beverage | In-kind items and services | $93.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) | Biogen, Inc. | $2,299 | 1 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | Biogen, Inc. | $1,040 | 11 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 4 | 60 | 60 | $20,263 | $5,257 |
| 2021 | 10 | 312 | 405 | $133,256 | $37,338 |
| 2020 | 14 | 366 | 439 | $151,334 | $38,167 |
Total Patients
738
Total Services
904
Medicare Billing
$80,762
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 15 | $6,435 | $1,866 | 29.0% |
| 97166 | Evaluation for occupational therapy, typically 45 minutes | Office | 2022 | 19 | 19 | $5,719 | $1,576 | 27.6% |
| 92610 | Evaluation of swallowing function | Office | 2022 | 15 | 15 | $4,710 | $1,079 | 22.9% |
| 97162 | Evaluation for physical therapy, typically 30 minutes | Office | 2022 | 11 | 11 | $3,399 | $735.77 | 21.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 69 | 93 | $39,897 | $13,987 | 35.1% |
| 97166 | Evaluation of occupational therapy, typically 45 minutes | Office | 2021 | 63 | 92 | $27,692 | $6,039 | 21.8% |
| 97162 | Evaluation of physical therapy, typically 30 minutes | Office | 2021 | 48 | 55 | $16,995 | $4,412 | 26.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 19 | 29 | $8,671 | $3,163 | 36.5% |
| 92610 | Evaluation of swallowing function | Office | 2021 | 26 | 33 | $10,362 | $2,249 | 21.7% |
| 97163 | Evaluation of physical therapy, typically 45 minutes | Office | 2021 | 24 | 25 | $7,750 | $2,105 | 27.2% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 21 | 23 | $7,774 | $2,002 | 25.7% |
| 95885 | Needle measurement and recording of electrical activity of muscles of arm or leg limited study | Office | 2021 | 18 | 24 | $5,208 | $1,348 | 25.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 11 | 18 | $4,968 | $1,050 | 21.1% |
| 95887 | Needle measurement and recording of electrical activity of head or trunk muscles | Office | 2021 | 13 | 13 | $3,939 | $983.45 | 25.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 68 | 86 | $36,894 | $10,654 | 28.9% |
| 97165 | Evaluation of occupational therapy, typically 30 minutes | Office | 2020 | 45 | 57 | $17,100 | $4,487 | 26.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 25 | 32 | $9,568 | $2,923 | 30.5% |
| 97161 | Evaluation of physical therapy, typically 20 minutes | Office | 2020 | 41 | 49 | $15,141 | $2,776 | 18.3% |
| 97166 | Evaluation of occupational therapy, typically 45 minutes | Office | 2020 | 31 | 36 | $10,836 | $2,746 | 25.3% |
| 92610 | Evaluation of swallowing function | Office | 2020 | 34 | 36 | $11,304 | $2,695 | 23.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 14 | 14 | $9,240 | $2,545 | 27.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 13 | 13 | $10,179 | $2,360 | 23.2% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2020 | 16 | 17 | $6,253 | $1,661 | 26.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 13 | 23 | $6,348 | $1,472 | 23.2% |
| 97163 | Evaluation of physical therapy, typically 45 minutes | Office | 2020 | 22 | 24 | $7,440 | $1,355 | 18.2% |
About Volkan Granit, M.D. MSC
Volkan Granit, M.D. MSC is a Neurology healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/30/2011. The National Provider Identifier (NPI) number assigned to this provider is 1194012930.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Volkan Granit, M.D. MSC has received a total of $9,198 in payments from pharmaceutical and medical device companies, with $1,148 received in 2021. These payments were reported across 26 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($4,488).
As a Medicare-enrolled provider, Granit has provided services to 738 Medicare beneficiaries, totaling 904 services with total Medicare billing of $80,762. Data is available for 3 years (2020–2022), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Bronx, NY
- Active Since 06/30/2011
- Last Updated 01/25/2013
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1194012930
Products in Payments
- Soliris (Drug) $3,060
- LATUDA (Drug) $15.60
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Bronx
Richard Lipton, Md, MD
Neurology — Payments: $982,914
Neurology $982,914
Michael Thorpy, Md, MD
Neurology — Payments: $451,587
Neurology $451,587
Rene Elkin, Md, MD
Neurology — Payments: $343,327
Neurology $343,327
Jelena Pavlovic, M.d, M.D
Neurology — Payments: $130,235
Neurology $130,235
Dr. Sandeep Gulati, D.o, D.O
Neurology — Payments: $124,853
Neurology $124,853
Dr. Lauren Gluck, Md, MD
Neurology — Payments: $53,848
Neurology $53,848